Imperial Capital Downgrades Medifast (MED) to In-Line

Go back to Imperial Capital Downgrades Medifast (MED) to In-Line

Medifast (MED) Tops Q3 EPS by 11c

November 5, 2014 5:29 PM EST

Medifast (NYSE: MED) reported Q3 EPS of $0.47, $0.11 better than the analyst estimate of $0.36. Revenue for the quarter came in at $74 million versus the consensus estimate of $76.1 million.

For earnings history and earnings-related data on Medifast (MED) click here.

... More